143 related articles for article (PubMed ID: 31261533)
21. Short communication: spectrum of non-Hodgkin lymphoma in an urban Ryan White-funded clinic in the established antiretroviral era.
Silverton A; Gunthel C; Adamski M; Mosunjac M; Nguyen ML
AIDS Res Hum Retroviruses; 2014 Jul; 30(7):665-9. PubMed ID: 24707838
[TBL] [Abstract][Full Text] [Related]
22. High survival rate in childhood non-Hodgkin lymphoma without CNS involvement: results of BFM 95 study in Kuwait.
Mottl H; Bajciova V; Nemec J; Al Shemmari S; Al Awadi S
Pediatr Hematol Oncol; 2003 Mar; 20(2):103-10. PubMed ID: 12554521
[TBL] [Abstract][Full Text] [Related]
23. Non-Hodgkin lymphoma in Uganda: a case-control study.
Parkin DM; Garcia-Giannoli H; Raphael M; Martin A; Katangole-Mbidde E; Wabinga H; Ziegler J
AIDS; 2000 Dec; 14(18):2929-36. PubMed ID: 11153674
[TBL] [Abstract][Full Text] [Related]
24. An Advanced AIDS Patient With CD4 <20 and Plasmablastic Lymphoma Achieving Complete Response With the V-EPOCH Regimen.
Nelson B; Hong A; Iqbal F; Venkatesan R
Cureus; 2020 Jun; 12(6):e8641. PubMed ID: 32685310
[TBL] [Abstract][Full Text] [Related]
25. Influence of molecular characteristics on clinical outcome in human immunodeficiency virus-associated non-Hodgkin's lymphoma: identification of a subgroup with favorable clinical outcome.
Kaplan LD; Shiramizu B; Herndier B; Hahn J; Meeker TC; Ng V; Volberding PA; McGrath MS
Blood; 1995 Apr; 85(7):1727-35. PubMed ID: 7535586
[TBL] [Abstract][Full Text] [Related]
26. Favourable outcomes for high-risk diffuse large B-cell lymphoma (IPI 3-5) treated with front-line R-CODOX-M/R-IVAC chemotherapy: results of a phase 2 UK NCRI trial.
McMillan AK; Phillips EH; Kirkwood AA; Barrans S; Burton C; Rule S; Patmore R; Pettengell R; Ardeshna KM; Lawrie A; Montoto S; Paneesha S; Clifton-Hadley L; Linch DC
Ann Oncol; 2020 Sep; 31(9):1251-1259. PubMed ID: 32464282
[TBL] [Abstract][Full Text] [Related]
27. High-dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone, cisplatin, and cytarabine in aggressive non-Hodgkin's lymphoma with partial response to front-line chemotherapy: a prospective randomized italian multicenter study.
Martelli M; Vignetti M; Zinzani PL; Gherlinzoni F; Meloni G; Fiacchini M; De Sanctis V; Papa G; Martelli MF; Calabresi F; Tura S; Mandelli F
J Clin Oncol; 1996 Feb; 14(2):534-42. PubMed ID: 8636768
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt's lymphoma: a retrospective analysis.
Barnes JA; Lacasce AS; Feng Y; Toomey CE; Neuberg D; Michaelson JS; Hochberg EP; Abramson JS
Ann Oncol; 2011 Aug; 22(8):1859-64. PubMed ID: 21339382
[TBL] [Abstract][Full Text] [Related]
29. AIDS-related Burkitt's lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy.
Lim ST; Karim R; Nathwani BN; Tulpule A; Espina B; Levine AM
J Clin Oncol; 2005 Jul; 23(19):4430-8. PubMed ID: 15883411
[TBL] [Abstract][Full Text] [Related]
30. Treatment of sporadic Burkitt lymphoma in adults, a retrospective comparison of four treatment regimens.
Oosten LEM; Chamuleau MED; Thielen FW; de Wreede LC; Siemes C; Doorduijn JK; Smeekes OS; Kersten MJ; Hardi L; Baars JW; Demandt AMP; Stevens WBC; Nijland M; van Imhoff GW; Brouwer R; Uyl-de Groot CA; Kluin PM; de Jong D; Veelken H
Ann Hematol; 2018 Feb; 97(2):255-266. PubMed ID: 29209924
[TBL] [Abstract][Full Text] [Related]
31. RD-CODOX-M/IVAC with rituximab and intrathecal liposomal cytarabine in adult Burkitt lymphoma and 'unclassifiable' highly aggressive B-cell lymphoma.
Corazzelli G; Frigeri F; Russo F; Frairia C; Arcamone M; Esposito G; De Chiara A; Morelli E; Capobianco G; Becchimanzi C; Volzone F; Saggese M; Marcacci G; De Filippi R; Vitolo U; Pinto A
Br J Haematol; 2012 Jan; 156(2):234-44. PubMed ID: 22098541
[TBL] [Abstract][Full Text] [Related]
32. Effectiveness of second line salvage chemotherapy with ifosfamide, carboplatin, and etoposide in patients with relapsed diffuse large B-cell lymphoma not responding to cis-platinum, cytosine arabinoside, and dexamethasone.
Simpson L; Ansell SM; Colgan JP; Habermann TM; Inwards DJ; Ristow KM; Johnston PB; Markovic SN; Micallef IN; Porrata LF; Witzig TE
Leuk Lymphoma; 2007 Jul; 48(7):1332-7. PubMed ID: 17613762
[TBL] [Abstract][Full Text] [Related]
33. Excellent real-world outcomes of adults with Burkitt lymphoma treated with CODOX-M/IVAC plus or minus rituximab.
Zhu KY; Song KW; Connors JM; Leitch H; Barnett MJ; Ramadan K; Slack GW; Abou Mourad Y; Forrest DL; Hogge DE; Nantel SH; Narayanan S; Nevill TJ; Power MM; Sanford DS; Sutherland HJ; Tucker T; Toze CL; Sehn LH; Broady R; Gerrie AS
Br J Haematol; 2018 Jun; 181(6):782-790. PubMed ID: 29741758
[TBL] [Abstract][Full Text] [Related]
34. Incidence and risk factors for relapses in HIV-associated non-Hodgkin lymphoma as observed in the German HIV-related lymphoma cohort study.
Schommers P; Gillor D; Hentrich M; Wyen C; Wolf T; Oette M; Zoufaly A; Wasmuth JC; Bogner JR; Müller M; Esser S; Schleicher A; Jensen B; Stoehr A; Behrens G; Schultze A; Siehl J; Thoden J; Taylor N; Hoffmann C
Haematologica; 2018 May; 103(5):857-864. PubMed ID: 29439188
[TBL] [Abstract][Full Text] [Related]
35. Malignant gastrointestinal lymphomas in patients with AIDS.
Heise W; Arastéh K; Mostertz P; Skörde J; Schmidt W; Obst C; Koeppen M; Weiss R; Grosse G; Niedobitek F; L'Age M
Digestion; 1997; 58(3):218-24. PubMed ID: 9243116
[TBL] [Abstract][Full Text] [Related]
36. Intermediate-grade lymphomas treated with cyclophosphamide-doxorubicin- vincristine-prednisone-bleomycin alternated with cyclophosphamide-methotrexate-etoposide-dexamethasone. Application of prognostic models to data analysis.
Velasquez WS; McLaughlin P; Fuller LM; Allen PK; Tucker SL; Swan F; Rodriguez MA; Hagemeister FB; Cabanillas FF
Cancer; 1994 May; 73(9):2408-16. PubMed ID: 7513251
[TBL] [Abstract][Full Text] [Related]
37. A multicenter trial of infusional etoposide, doxorubicin, and vincristine with cyclophosphamide and prednisone (EPOCH) in patients with relapsed non-Hodgkin's lymphoma.
Wilder DD; Ogden JL; Jain VK
Clin Lymphoma; 2001 Mar; 1(4):285-92. PubMed ID: 11707843
[TBL] [Abstract][Full Text] [Related]
38. Modified magrath regimens for adults with Burkitt and Burkitt-like lymphomas: preserved efficacy with decreased toxicity.
Lacasce A; Howard O; Lib S; Fisher D; Weng A; Neuberg D; Shipp M
Leuk Lymphoma; 2004 Apr; 45(4):761-7. PubMed ID: 15160953
[TBL] [Abstract][Full Text] [Related]
39. CODOX-M/IVAC (NCI 89-C-41) in children and adolescents with Burkitt's leukemia/lymphoma and large B-cell lymphomas: a 15-year monocentric experience.
Moleti ML; Testi AM; Giona F; Malandruccolo L; Pescarmona E; Martino P; Paoloni F; Barberi W; Palumbo G; Mandelli F; Foa R
Leuk Lymphoma; 2007 Mar; 48(3):551-9. PubMed ID: 17454598
[TBL] [Abstract][Full Text] [Related]
40. High-dose cytosine-arabinoside and cisplatin regimens as salvage therapy for refractory or relapsed AIDS-related non-Hodgkin's lymphoma.
Bi J; Espina BM; Tulpule A; Boswell W; Levine AM
J Acquir Immune Defic Syndr; 2001 Dec; 28(5):416-21. PubMed ID: 11744828
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]